Data from cell culture and animal models of prion disease support the separate involvement of both heparan sulfate proteoglycans and copper (II) Significantly, a peptide of this sequence is able to inhibit the binding of full-length prion molecule to heparin, suggesting a direct role in heparin recognition within the intact protein. The collective data suggest a complex interaction between prion protein and heparin/ heparan sulfate and has implications for the cellular and pathological functions of prion proteins.
Introduction
Considerable effort is being devoted to the identification of natural receptors for prion protein (PrP) both to refine our understanding of prion metabolism and to reveal potential targets for therapeutic intervention in the transmissible spongiform encephalopathies (TSEs). One group of potential co-factors are the glycosaminoglycans (GAGs) and in particular membrane proteins and extracellular matrix components elaborated with heparan sulfate (HS) sugar chains. Heparan sulfates (of which heparin is a heavily sulfated variant) are expressed on a wide variety of cell types, including those of neural origin, and modulate the activity of a wealth of cell-surface and extracellular signaling molecules such as growth factors and cytokines (1, 2) . In the TSE field it is known that HS proteoglycans (HSPGs) co-localize with the insoluble aggregates of the prion (PrP Sc ) that accumulate in the brain tissue of TSE affected animals (3) (4) (5) . They also promote the formation of amyloid structures typical of Alzheimer's disease when co-injected into the brains of rats with A -protein (6) . Furthermore, administration of select anionic compounds can restrict both tissue-specific accumulation of PrP Sc and the onset of neurodegenerative features in experimental models of prion disease. In this respect pentosan sulfate and DS500 (dextran sulfate with av. MW 500,000) are particularly effective (7) (8) (9) . The basis for the anti-prion activity of these compounds is uncertain; one suggestion is that they compete with endogenous HSPGs for prion, another that they stabilise conformations of PrP sc which are not favoured as templates for 4 resistant folding-variant can be stimulated by the addition of HS (17) and an heparitinasesensitive fraction of a cell extract will promote the reconstitution of infectivity to DMSOdispersed prion rods (18) . Additionally, the 37 kDa/67 kDa laminin receptor (LRP/LR), originally proposed as a potential binding partner for PrP (19) has now been confirmed as the cell surface receptor (20) . Heparan sulfate proteoglycans (HSPGs) have been identified as co-receptors in this interaction via HS-binding domains on both proteins (21) .
A notable feature of prion biology is the chelation of divalent cations such as copper (22) (23) (24) and there is considerable interest in possible connections between metal-binding status and conformation (25) (26) (27) (28) (29) (30) . Intriguingly manganese and copper have quite distinct effects on the adoption of proteinase resistance by PrP (29) . Metal binding resides primarily in an octapeptide repeat motif between residues 53-93 of mammalian PrP though more distal binding sites have also been proposed (24, 30) . The role of the octapeptide repeat in prion disease progression is poorly understood. Though PrP null-mutant mice can be restored to scrapie susceptibility by introduction of PrP transgenes lacking this motif (31, 32) , scrapie incubation times are still extended compared to wild type (33) .
Combined heparin-binding activity and divalent cation chelation have been demonstrated for several other proteins, notably superoxide dismutase (34) and the APP protein of Alzheimer's disease (35) . An interaction between the heparin-and copper-binding functions of PrP would be very interesting and there is certainly evidence that the two functions map to the same region of the molecule. Shyng and colleagues have reported that the region between residues 25 and 91 of PrP (incorporating the octapeptide repeat region) is sufficient for PrP binding to HSPG moieties on N2a cells. They also demonstrated that the surface expression of a mutant PrP lacking this Nterminal segment, unlike intact PrP c , is not subject to down-regulation induced by soluble pentosan polysulfate (36) . Elsewhere, it has been shown that a naturally truncated PrP present in 5 significant amounts in the human brain and lacking residues amino-terminal to 111 or 112
(including the octapeptide-repeat), has no heparin-binding activity (37) . Lastly, the PrP sequence aa53-93 is directly involved in an HSPG-dependent interaction between recombinant PrP and the 37kDa/67kDa laminin receptor precursor (LRP/LR) (21) . Significantly, whereas Caughey reported heparin binding by PrP c that was independent of divalent ion concentration (14) a study by Brimacombe et al. describes heparin-sensitive binding of recombinant PrP to experimental nickel surfaces (15) .
The only other region of PrP with supporting evidence for a role in GAG binding is a central, hydrophobic and amyloidogenic sequence between residues 106-126 (38, 39) . This sequence undoubtedly plays a major role in the biosynthesis of the protease-resistant form of PrP (PrP Sc ).
Cells expressing engineered variants of PrP c deleted for residues in this region of the molecule do not support the propagation of homologous PrP Sc , and PrP molecules deleted for this sequence cannot be converted to protease-resistant forms in vitro (40) . Several groups have investigated the cytotoxic properties of the central region (41, 42) and significantly a neurotoxic activity associated with a peptide corresponding to residues 106-126 is abrogated by soluble heparin and related GAGs (43) . Though copper has been shown to affect the aggregation and neurotoxic properties of this region (24) , the influence of copper ions on any interaction between this sequence and GAGs has yet to be reported.
Recombinant PrP has now been expressed and purified by several groups (44) (45) (46) . These efforts have yielded proteins that resemble PrP c in that they fold into alpha-helical and -sheeted structures (20, 46) . They are also proteinase K sensitive (47) , suggesting a lack of infectivity.
Crucially for this study, N-terminally-tagged PrP retains propagating activity (48) and PrP tagged with glutathione sulfotransferase (GST) retains Hsp60 chaperone binding activity (49) .
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Biotinylation of heparin and HS for immobilisation
Three methods were chosen for biotin labeling of the heparins and HS used in this study: a.)
GAGs were labeled by reaction of their aldehydic reducing groups using a method based on bovine serum albumin in PBS containing 0.2% tween-20 (2 hours at room temperature).
GST::haPrP c was subsequently applied at 1µg/ml in PBS containing 3% BSA. After 2 hours incubation the plate was thoroughly washed (6 x in PBS/ 0.05% tween-20) and bound GST::haPrP c detected with polyclonal rabbit anti-GST/ anti-rabbit Ig (F(ab') 2 )-peroxidase conjugate as described above (conventional heparin-binding ELISA). In inhibition studies a selection of GAGs were included (100 µg/ml) during the GST::haPrP c incubation phase. An ELISA for heparin / HS binding by GST-tagged PrP c proteins and peptides was developed to confirm the findings of biosensor analysis. Fig. 3a shows the result of titration of GST::haPrP c on two types of heparin (bovine lung and porcine intestinal heparin) and porcine mucosal HS.
Results

Recombinant hamster PrP
Copper (II) was not added in these experiments. Binding to the two heparins was comparable and much more extensive than that achieved on HS-coated wells, but for both GAGs (heparin and HS) was dose dependent. were the most potent inhibitors of heparin binding (on a weight / volume basis). The heparins were substantially weaker and both the low molecular weight porcine intestinal heparin (LMW PIH) and two sources of HS were without effect. When copper (II) was added, the inhibitory activity of the GAGs/ polysaccharides was generally increased. Intact PIH (and also BLH, data not shown) approached DS and PPS in inhibitory effect and the binding of GST::haPrP to PIH could be weakly (but incompletely) disrupted by LMW PIH. These findings support the earlier evidence that Cu (II) reduces the interaction between full-length hamster PrP and heparin.
In a separate experiment human recombinant PrP c was allowed to bind to PI-heparin in the presence of a number of GAGs and modified heparins, added at 10 and 100 µg/ml (Fig. 4) . Again BLH was a good inhibitor of heparin-binding, whereas PMHS had essentially no effect. Both persulfated (oversulfated) heparin and selectively de-6-O-sulfated heparin were less effective inhibitors than unmodified BLH. Selectively de-2-O-sulfated heparin lacked inhibitory activity completely at 10 µg/ml and inhibited only weakly at 100 µg/ml. These results indicate an important role for 2-O-sulfate groups in the prion-heparin interaction. Interestingly, low concentrations of 2-O-desulfated heparin, like CS (Fig. 3c ) appeared to promote PrP c binding to immobilised heparin.
Binding of GST:: hamster PrP peptide fusions and synthetic PrP peptides (of human sequence) to immobilised heparin / HS
To identify regions of the PrP molecule with independent heparin / HS binding activity, recombinant GST::fusions of partial hamster PrP sequences collectively spanning the entire hamster prion sequence (21, 44) were injected over a heparin-derivatised biosensor surface. When several independent batches of peptides were tested (in each case no more than 2 months after expression-purification), P2 (53-93) and P4n (110-128) consistently gave the most significant binding to heparin (Fig. 5a ). P1, P3, P4, P5 and Px generally yielded weak biosensor responses, although significant binding of P1 and P5 to heparin was recorded in occasional batches. Note that the increase in signal resulting from P4n injection was not reversed by high salt, weak acid, alkaline or soluble heparin washes: procedures which should have disrupted all but the strongest electrostatic interactions. Peptides were tested in succession (as in Fig. 5a ) and individually with no evidence of sample order-related enhancement or reduction of signal strength for any peptide.
In some experiments FGF-receptor (a known heparin-binding protein) was injected before and after a series of the PrP peptides and no change was observed in the extent of binding of this protein (data not shown).
Subsequent experiments revealed that the heparin-binding activity of both GST:: P2 (53-93) and GST:: P4n (110-128) were sensitive to copper (II) addition, elevating and suppressing biosensor response respectively. GST:: haPrP P2 (53-93) produced the most significant response when applied to the HS-derivatised biosensor surface but in contrast to its binding of heparin, recognition of HS was not influenced by Cu (II) (data not shown).
Although GST itself displays no heparin-binding activity in the buffer conditions chosen for GST:: haPrP/peptides (data not shown), it is conceivable that the GST portion of the fusion peptides could influence heparin binding activities of the attached PrP sequence. Indeed it may explain the inconsistent binding observed for some GST-linked peptides (e.g. GST::P5 (218-231).
For this reason synthetic PrP peptides containing no tag were also tested for binding to bovine lung heparin (Fig. 5b) . In biosensor analysis low molecular weight entities such as small peptides tend to produce relatively weak signals per mol of bound analyte. By working at high sample concentrations however (e.g. 0.1-1.0 mg/ml) the signal strength can be maximised, so long as surface binding sites are non-limiting. Such data should be interpreted with caution however as high analyte concentrations can produce rate-limiting diffusional artefacts, re-binding phenomena, and increase the tendency for self-self interactions. Of the seven synthetic peptides only P1 (23-52), P2 (53-93) and P4n (110-128) yielded significant biosensor responses indicating that these three sequences are the strongest candidate heparin/ HS-binding regions in the prion molecule. As with the GSTtagged peptides the synthetic peptides were injected singly and in different order with no effect on the patterns of binding.
All GST-fusion peptides were tested for heparin binding by ELISA (synthetic peptides with no GST were not detectable in this method). Only GST:: P1 (23-52) bound heparin reproducibly, providing a signal that could be selectively inhibited (Fig. 6a) GAGs in a concentration dependent manner (Fig. 7a, b) . Heparin recognition was successfully competed with soluble heparin (data not shown). Porcine intestinal HS, though a weak inhibitor of the binding of synthetic P2 to immobilised heparin (data not shown) was an effective competitor for the binding of P2 to an HS-derivatised surface (Fig. 7c) . It was noted that P2 (53-93) bound to the HS-derivatised surface in the presence of soluble PMHS was more readily eluted with the wash sequence (BLH, NaCl, NaOH) than P2 bound in the absence of competitor.
Copper (II) ions substantially enhance the heparin binding activity of synthetic peptide P2 (53-
93)
As P2 (53-93) encompasses a region of PrP containing motifs for copper binding, biosensor experiments were conducted to assess any influence of copper availability on the heparin binding activity of this peptide. The biosensor response produced by 1 mg/mL P2 (53-93) was substantially enhanced (~ 7-fold) by the addition of 10µM Cu (II) (Fig. 8a) . Intriguingly a second injection of P2 peptide (without added copper) applied immediately after one containing Cu (II) generated a higher signal (ca. 2-3 fold) than the initial injection of P2 onto a washed heparin surface. This result strongly suggested that a proportion of the enhancing activity of Cu (II) might be exercised as a complex with the heparin substrate. To investigate this further we compared the accumulation of synthetic P2 on the heparin surface after two pre-treatments: i.) after injection of Cu (II) alone and ii.) after injection of Cu (II) followed by EGTA (a potent chelator of copper) (Fig. 8b) . Injection of a brief pulse of EGTA between injections of Cu (II) and P2 greatly reduced the enhancement possible by pre-treatment with Cu (II) alone. In a demonstration of the selectivity of this effect no such enhancement was recorded when Cu (II) was applied in advance P1 peptide (Fig. 8b) or P4n peptide (data not shown). To assess the ability of alternative metals to enhance heparin-binding by P2 (53-93), P2 (53-93) the peptide was injected in the absence of additional cation and also in the presence of 50µM copper (II), magnesium (II), nickel (II) or manganese (II) (Fig. 8c) . None of the alternative cations replicated precisely the action of copper.
Neither magnesium (II) or manganese (II) affected binding significantly and although nickel (II)
induced a larger absolute response, the rapid return of signal to baseline at completion of the contact period was indicative of a highly weak interaction. Since copper (II) had an inhibitory influence on binding of PrP to heparin in the range 0-2 µM (Fig. 3b) , we decided to apply P2 peptide in a range of Cu (II) concentrations (Fig. 8d) . The greatest enhancing activity was afforded at relatively high concentrations (>10 µM) whereas in the concentration range that inhibits full-length PrP binding to heparin, Cu (II) had no clear influence on synthetic P2 peptide.
Competitive ELISA to determine the relevance of P1, P2 and P4n sequences in the binding of full-length GST::haPrP c to heparin
To access which sequences, singly or in combination, might contact heparin within the fully folded recombinant GST:: haPrP c molecule a competition ELISA was developed in which GST:: haPrP c was incubated on heparin in the presence of synthetic peptides P1, P2 and P4n (Fig. 9 ).
As the 2 o antibody in this ELISA recognises GST, only heparin-bound GST:: haPrP c was Fig. 9 ). The direct ELISA (Fig. 3b) proved that this inhibition was only partial i.e. that a significant proportion of heparin affinity still remains even at high concentrations of copper. This suggests that copper alters the conformation of PrP rather than simply shielding binding sites in the heparin substrate. Another explanation which we cannot rule out is that the main effect of copper ions is disrupt oligomers/aggregates of PrP bound to heparin rather than inhibition of the PrP-heparin interaction directly, hence the incomplete inhibition. Nickel (II) and zinc (II), but not manganese (II) ions were also inhibitory, though not as strongly as copper. A related effect was first described by
Brimacombe et al., who reported that recombinant PrP could be displaced from an experimental nickel biosensor surface by pulses of heparin (15) . PrP loaded with copper and manganese assumes distinct conformations with differing levels of protease-resistance (25) (26) (27) (28) (29) (30) . Our data suggests that one of the first consequences of metal-induced conformational changes might be an altered affinity for endogenous HSPGs. The reverse situation, that bioactive HSPGs might influence the uptake of metal ions by PrP is also a possibility.
The specificity of the PrP-heparin interaction was also investigated. The interaction of PrP with heparin (as detected by the ELISA) could be disrupted by soluble heparin, HS and by other sulfated polysaccharides (Fig. 3c, d and Fig. 4 ) but was refractory to inhibition by CS, confirming earlier work by others (14) . This last observation on the non-activity of CS has a special significance as it suggests that presentation of sulfates is not in itself sufficient for prion-binding activity. A particularly interesting finding was the potent inhibitory activity of a fraction of dextran sulfate of average MW 8000 (DS8). On a weight / volume basis this preparation was found to be superior to heparin and at least as effective as pentosan polysulfate (PPS), a polyanion with well-documented anti-prion activities in tissue culture and animal models (36, 7) .
It would be of great interest to compare the inhibitory activity of DS8 with fractions of higher MW such as DS500 (average MW 500,000) which is a particularly effective inhibitor of PrP sc propagation in cell culture (13) and a potent anti-prion agent in animal studies of prion disease (8, 9) . Using this competition ELISA we also explored the contribution to prion binding of 2-and 6-O sulfate groupings, two of the three types of sulfate which elaborate heparin and HS (N-sulfates
were not examined in this study). Removal of 2-O sulfates was found to significantly reduce the inhibitory activity of BLH in the competitive ELISA (Fig. 4) , suggesting an important role in prion-ligation. FGF-2 and hepatocyte growth factor are other heparin-binding proteins with a particular requirement for 2-O sulfate (56) .
The location of heparin-binding sites in the prion protein has not previously been determined with certainty. This study revealed three sites in recombinant PrP with independent affinity for GAGs:
amino acids 23-52, 53-93 and 110-128. Whilst the first sequence has no previously reported affinity for GAGs, there is some evidence for GAG binding activity at the other two sites (21, 36, 37, 43) . The biosensor response generated by P2 (53-93) on both heparin and HS surfaces was concentration-dependent and selectively inhibited and so is least likely to be artefactual. In (Fig. 6a) . However, since we were unable to demonstrate competition between this peptide and full-length GST::haPrP c for binding to heparin (Fig. 9a, b) we propose that this sequence is not a major heparin-binding site in intact PrP c . A more important association may be with sequences within PrP itself for we were able to demonstrate affinity for GST::haPrP c (Fig.   6b ). Such an interaction may be a means by which the putative acceptor molecules for this sequence such as nucleic acids (55) and Hsp60-like chaperonins might influence PrP function.
In biosensor analysis P4n (110-128) bound heparin and HS both as GST::fusion and free peptide, but was not positive in the ELISA. This peptide particularly yielded biosensor signals that could not be reversed by salt washing or extremes of pH. A possible explanation for this unusual behaviour is extensive aggregate formation either in solution or in situ at the heparin surface especially as a related sequence (106-126) shows a well described propensity for fibril formation (38, 39) . Significantly the β−sheeted structures characteristic of peptide 106-126 in weakly acidic ionic buffers (conditions in which fibrils are also favoured) are evidently highly stable (resistant to 5% SDS or alkali to pH 12) (39). That P4n should show an affinity for heparin/HS was of interest as it has shown elsewhere that the cytotoxic properties of peptide 106-126 may be abrogated by GAGs (43) . Again, as an excess of P4n (110-128) was not seen to interfere with the binding of full-length PrP to heparin this peptide is considered a weak candidate for a true physiological role in heparin/ HS binding by PrP
The findings in this study support a prominent role for P2 were washed with 10 µl BLH (2 mg/ml), 10 µl 2 M NaCl and 5 µl 10 mM NaOH. 
